Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation

Ther Adv Cardiovasc Dis. 2011 Feb;5(1):23-31. doi: 10.1177/1753944710391925. Epub 2010 Dec 23.

Abstract

Background: Optimal antithrombotic therapy after percutaneous coronary intervention (PCI) is currently undefined in patients requiring long-term anticoagulation. Previous studies comparing triple therapy (TT) of warfarin, aspirin and clopidogrel with standard dual therapy (DT) of aspirin and clopidogrel have yielded conflicting results. Meta-analysis of these studies was performed to evaluate safety and efficacy of TT.

Methods: A total of 1482 patients from 6 studies were analyzed using the Mantel-Haenszel random effect model to extract incidence of major bleeding. The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications). The incidence of MACEs was computed using the Mantel-Haenszel fixed effect model. Combined relative risks (RRs) across all of the studies and the 95% confidence intervals (CIs) were determined. A two-sided alpha error <0.05 was considered statistically significant.

Results: Baseline characteristics were similar in both groups. Compared with patients receiving DT, the risk of major bleeding was significantly higher in the TT group (RR: 2.74, CI: 1.08-6.98; p=0.034). However, risk of MACE was significantly lower in the TT group (RR: 0.72, CI: 0.56-0.98; p=0.014).

Conclusion: In patients requiring long-term anticoagulation after PCI, TT may be superior to DT in reducing the incidence of MACEs, however risk of major bleeding complications is increased significantly.

Publication types

  • Meta-Analysis

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects*
  • Angioplasty, Balloon, Coronary / mortality
  • Anticoagulants / adverse effects*
  • Aspirin / adverse effects
  • Clopidogrel
  • Drug Therapy, Combination
  • Fibrinolytic Agents / adverse effects*
  • Hemorrhage / chemically induced*
  • Hemorrhage / mortality
  • Humans
  • Patient Selection
  • Risk Assessment
  • Risk Factors
  • Thrombosis / etiology
  • Thrombosis / mortality
  • Thrombosis / prevention & control*
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives
  • Time Factors
  • Treatment Outcome
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Warfarin
  • Clopidogrel
  • Ticlopidine
  • Aspirin